CA2652025A1 - Flourescent dyes for use in glucose sensing - Google Patents
Flourescent dyes for use in glucose sensing Download PDFInfo
- Publication number
- CA2652025A1 CA2652025A1 CA002652025A CA2652025A CA2652025A1 CA 2652025 A1 CA2652025 A1 CA 2652025A1 CA 002652025 A CA002652025 A CA 002652025A CA 2652025 A CA2652025 A CA 2652025A CA 2652025 A1 CA2652025 A1 CA 2652025A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- hpts
- making
- compound
- equal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
- C09B57/001—Pyrene dyes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Abstract
A novel class of compounds that includes HPTS-Cys-MA, and methods of making them are disclosed herein. The class of compounds including HPTS-Cys-MA are useful as fluorescent dyes for analyte detection.
Description
FLUORESCENT DYES FOR USE IN GLUCOSE SENSING
RELATED APPLICATIONS
This application claims the benefit of US Provisional Application No.
60/833,081 filed July 25, 2006 which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention Novel fluorescent dyes are disclosed for use in analyte detection.
Description of the Related Art Fluorescent dyes, including 8-hydroxypyrene-1,3,6-trislfonic acid (HPTS) and its derivatives, are known and have been used in analyte detection. See e.g., U.S.
Patent Nos.
6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5.763_238; and co-pending U.S. Patent Appl. Nos.
10/456,895 and 11/296,898; each of whicli is incorporated herein in its entirety by reference thereto.
SUMMARY OF THE INVENTION
Fluorescent dyes having the below generic structure are disclosed in accordance with embodiments of the present invention.
H O
N-S OH
H O~ I 0 H
N-S S-N
wherein:
RELATED APPLICATIONS
This application claims the benefit of US Provisional Application No.
60/833,081 filed July 25, 2006 which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention Novel fluorescent dyes are disclosed for use in analyte detection.
Description of the Related Art Fluorescent dyes, including 8-hydroxypyrene-1,3,6-trislfonic acid (HPTS) and its derivatives, are known and have been used in analyte detection. See e.g., U.S.
Patent Nos.
6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5.763_238; and co-pending U.S. Patent Appl. Nos.
10/456,895 and 11/296,898; each of whicli is incorporated herein in its entirety by reference thereto.
SUMMARY OF THE INVENTION
Fluorescent dyes having the below generic structure are disclosed in accordance with embodiments of the present invention.
H O
N-S OH
H O~ I 0 H
N-S S-N
wherein:
R is H
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3-, HPO3-, O
CO2 - and ),and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
11 R4 ]s -C-R5;
Y-(CH2)-R6 Y+ H2n, OHCHz~R6 5 Ris selected from the group consisting of n and n wherein n is equal to 1-10, n' is equal to 2-4, and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR~, OR~ and COZH; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styiyl, acrylamido and methacrylamido.
Fluorescent dyes having the below generic structure are disclosed in accordance witli preferred embodiments of the present invention.
R$ N u N-S
a~N R3 O\ I O R3 N~ s R ~N-S SN R
O
O O O
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HPO3-, COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected fi-oin the group consisting of alkyl, alkylaryl and aromatic groups);
g (CHZ)-Rs -(CH)0~-R is selected from the group consisting of n and n n wherein n is equal to 1-10, n" is equal to 2-4;
R9 is selected from the group consisting of NHR ' , OR " and CO2H; and Rl is H or an etllylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
A fluorescent dye terined HPTS-Cys-MA (or HPTS-TriCys-MA) having the below structure is disclosed in accordance with preferred embodiments of the present invention.
Bu4NO3S
~H H O
N,_,,~ N H S 11 H
n O
O O O Bu4NO3S Doc-S I I SO3NBu4 N5 N ~ NNH SH
O O O O O O
HPTS-CysMA
A glucose sensor is disclosed in accordance with another embodiment of the present invention, comprising the dyes disclosed herein (e.g., HPTS-Cys-MA) and a quencher comprising boronic acid, such as 3,3'-oBBV.
A first method of making the generic class of compounds to which HPTS-Cys-MA
belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:
O O
Z protection coupling O
HO R2-NH2 HO11~R2-NZ H2N R5 R N''R2-NZ
H
H 101 Z deprotect N-S OH
R2 p I
VIV, HPTS -CI R5 H H H R-NH2 N-S -N
ii ii 2 wherein:
R' is H-R
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03, C02- and ), and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R4 is -uC-R5;
Y-(CH2)-R6 Y+HZn, OHCH&R6 R 5 is selected from the group consisting of n and n wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and 0;
R6 is selected from the group consisting of NHR~, OR~ and COZH;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).
A second method of making the generic class of compounds to wl7icll HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention.
The method comprises the steps of:
H0~
N-~ OH
HPTS-CI
HO NEt3, CH2CIZ 3 3 R3 HO R ~ 0 R
\ Q ~OH
HS S-H
R$-NH2 EDC,HOBt NEt3, CH2CI2 R$ N-~ / OH
/ I I
H
j O
Rs'NN_S S_N~yN Ra H H
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03-, CO-)- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
8. -(CHz)-Rs HCH2OHCH2R9 R is selected from the group consisting of n and n "
wlierein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR'O and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
A specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making HPTS-CysOH as follows:
cl-S OAc o ~ I I
CI-S S CI HO ~
11 it ~ It 0 p HPTS-CI 0 H 0 ~
NBu4OH r HO)~NH2 H2O Ho NH2 NEt3, CH2C12 Bu4N03S I S03NBu4 S03H 2 S03NBU4 HO 0~ 0 OH
N-S S-N
O H O O H O
HPTS-CysOH
and making HPTS-Cys-MA as follows:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3-, HPO3-, O
CO2 - and ),and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
11 R4 ]s -C-R5;
Y-(CH2)-R6 Y+ H2n, OHCHz~R6 5 Ris selected from the group consisting of n and n wherein n is equal to 1-10, n' is equal to 2-4, and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR~, OR~ and COZH; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styiyl, acrylamido and methacrylamido.
Fluorescent dyes having the below generic structure are disclosed in accordance witli preferred embodiments of the present invention.
R$ N u N-S
a~N R3 O\ I O R3 N~ s R ~N-S SN R
O
O O O
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HPO3-, COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected fi-oin the group consisting of alkyl, alkylaryl and aromatic groups);
g (CHZ)-Rs -(CH)0~-R is selected from the group consisting of n and n n wherein n is equal to 1-10, n" is equal to 2-4;
R9 is selected from the group consisting of NHR ' , OR " and CO2H; and Rl is H or an etllylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
A fluorescent dye terined HPTS-Cys-MA (or HPTS-TriCys-MA) having the below structure is disclosed in accordance with preferred embodiments of the present invention.
Bu4NO3S
~H H O
N,_,,~ N H S 11 H
n O
O O O Bu4NO3S Doc-S I I SO3NBu4 N5 N ~ NNH SH
O O O O O O
HPTS-CysMA
A glucose sensor is disclosed in accordance with another embodiment of the present invention, comprising the dyes disclosed herein (e.g., HPTS-Cys-MA) and a quencher comprising boronic acid, such as 3,3'-oBBV.
A first method of making the generic class of compounds to which HPTS-Cys-MA
belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:
O O
Z protection coupling O
HO R2-NH2 HO11~R2-NZ H2N R5 R N''R2-NZ
H
H 101 Z deprotect N-S OH
R2 p I
VIV, HPTS -CI R5 H H H R-NH2 N-S -N
ii ii 2 wherein:
R' is H-R
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03, C02- and ), and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R4 is -uC-R5;
Y-(CH2)-R6 Y+HZn, OHCH&R6 R 5 is selected from the group consisting of n and n wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and 0;
R6 is selected from the group consisting of NHR~, OR~ and COZH;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).
A second method of making the generic class of compounds to wl7icll HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention.
The method comprises the steps of:
H0~
N-~ OH
HPTS-CI
HO NEt3, CH2CIZ 3 3 R3 HO R ~ 0 R
\ Q ~OH
HS S-H
R$-NH2 EDC,HOBt NEt3, CH2CI2 R$ N-~ / OH
/ I I
H
j O
Rs'NN_S S_N~yN Ra H H
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03-, CO-)- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
8. -(CHz)-Rs HCH2OHCH2R9 R is selected from the group consisting of n and n "
wlierein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR'O and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
A specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making HPTS-CysOH as follows:
cl-S OAc o ~ I I
CI-S S CI HO ~
11 it ~ It 0 p HPTS-CI 0 H 0 ~
NBu4OH r HO)~NH2 H2O Ho NH2 NEt3, CH2C12 Bu4N03S I S03NBu4 S03H 2 S03NBU4 HO 0~ 0 OH
N-S S-N
O H O O H O
HPTS-CysOH
and making HPTS-Cys-MA as follows:
0 Bu4NO3S
N~~NH3CI NN ~
II H H-S OH
EDC, HBtu, HOBt HPTS-CysOH
DIEA, DMF Bu4N03S ~ I ( S03NBU4 N,N ~ ~ N_/~N\
HS SH (~
HPTS-CysMA
Another specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making:
a) TBCys as follows:
NHz NBu40H, H20NH
HO H0~ 2 SO3H S03N Bu4 cysteic acid TBCys b) Phth acid as follows:
0 o 0 ~NHz + 0 I\ 4 A MS ~NPhth + DIEA
HO / CHC13, DIEA HO
S03NBU4 0 reflux. %
h S03NBU4 100 /u TBCys Phth acid c) Phth MA as follows:
N Phih ` ~
HO + ~ \HN NH3C1 EDC, HOBT, NEt3 ~HHNPhth S03N Bu4 CH2CI2 S03NBU4 Phth MA
Phth acid 72%
d) AminoCysMA as follows:
0 0 F~N-NH2 H20 O H O
~~ NPMh Et~ ~--"--, NH2 Nl~
N H H H
5O~NBU4 80 C, 2 h S03NBU4 PhthMA AninoCysMA ~ and ~
N~~NH3CI NN ~
II H H-S OH
EDC, HBtu, HOBt HPTS-CysOH
DIEA, DMF Bu4N03S ~ I ( S03NBU4 N,N ~ ~ N_/~N\
HS SH (~
HPTS-CysMA
Another specific method for making HPTS-Cys-MA is disclosed in accordance with another embodiment of the present invention. The method comprises the steps of making:
a) TBCys as follows:
NHz NBu40H, H20NH
HO H0~ 2 SO3H S03N Bu4 cysteic acid TBCys b) Phth acid as follows:
0 o 0 ~NHz + 0 I\ 4 A MS ~NPhth + DIEA
HO / CHC13, DIEA HO
S03NBU4 0 reflux. %
h S03NBU4 100 /u TBCys Phth acid c) Phth MA as follows:
N Phih ` ~
HO + ~ \HN NH3C1 EDC, HOBT, NEt3 ~HHNPhth S03N Bu4 CH2CI2 S03NBU4 Phth MA
Phth acid 72%
d) AminoCysMA as follows:
0 0 F~N-NH2 H20 O H O
~~ NPMh Et~ ~--"--, NH2 Nl~
N H H H
5O~NBU4 80 C, 2 h S03NBU4 PhthMA AninoCysMA ~ and ~
e) HPTS-Cys-MA as follows:
NaO3S
N~ 0 NN
N $ OH
0 0 1. HPTS-CI 0 0 H 0 ~
~NH2 2. NaOH
H H 3. ion exchange Na03S ~ I I S03Na S03NBu4 4. PS resin H H
~
~
N N N S S N N N
AminoCysMA 0 0 H 0 0 11 H 0 0 HPTS-TriCys-MA
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Stern-Volmer Quenching of HPTS-CysMA/3,3'-oBBV in Solution.
Shows the relative emission change (Stem-Volmer curve) upon addition of 3,3'-oBBV
indicating the quenching of HPTS-CysMA with 3,3'-oBBV.
Figure 2. Glucose Response of HPTS-CysMA/3,3'-oBBV in Solution. Shows the fluorescence emission measured after addition of glucose to HPTS-CysMA and 3,3'-oBBV.
Figure 3. Fluorescence Spectra of HPTS-CysMA in Hydrogel. Shows fluorescence excitation and emission spectra of a polymer hydrogel comprising HPTS-CysMA.
Figure 4. Time Drive of HPTS-Cys-MA in hydrogel at Different pHs, Em = 532 nm. Shows time drive of HPTS-CysMA in hydrogel at different pH's.
Figure 5. pH profile of HPTS-Cys-MA at two different excitations, Em = 532 nm.
Shows pH profile of HPTS-CysMA at two different excitation wavelengths.
Figure 6. Glucose Response of HPTS-CysMA/3,3'-oBBV in hydrogel. Shows the glucose response of HPTS-CysMA/3,3'-oBBV in a hydrogel.
Figure 7 Fluorescence Spectra of HPTS-CysMA and HPTS-LysMA. Shows a comparison of the fluorescence spectra of HPTS-Cys-MA and HPTS-Lys-MA. (1 x 10-5 M);
Ex Slit 8 nm, Em Slit 12 nm.
Figure 8 Comparison of Stem-Volmer Quenching Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV, [Dye] = 1x10-5 M. Shows a comparison of 3,3'-oBBV Stern-Volmer quenching study using HPTS-Cys-MA and HPTS-Lys-MA.
Figure 9 Comparison of Glucose Modulation Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV; [Dye] = Ix10-5 M; Q/D = 150. Shows a comparison glucose modulation using HPTS-Cys-MA and HPTS-Lys-MA with 3,3'-oBBV.
NaO3S
N~ 0 NN
N $ OH
0 0 1. HPTS-CI 0 0 H 0 ~
~NH2 2. NaOH
H H 3. ion exchange Na03S ~ I I S03Na S03NBu4 4. PS resin H H
~
~
N N N S S N N N
AminoCysMA 0 0 H 0 0 11 H 0 0 HPTS-TriCys-MA
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Stern-Volmer Quenching of HPTS-CysMA/3,3'-oBBV in Solution.
Shows the relative emission change (Stem-Volmer curve) upon addition of 3,3'-oBBV
indicating the quenching of HPTS-CysMA with 3,3'-oBBV.
Figure 2. Glucose Response of HPTS-CysMA/3,3'-oBBV in Solution. Shows the fluorescence emission measured after addition of glucose to HPTS-CysMA and 3,3'-oBBV.
Figure 3. Fluorescence Spectra of HPTS-CysMA in Hydrogel. Shows fluorescence excitation and emission spectra of a polymer hydrogel comprising HPTS-CysMA.
Figure 4. Time Drive of HPTS-Cys-MA in hydrogel at Different pHs, Em = 532 nm. Shows time drive of HPTS-CysMA in hydrogel at different pH's.
Figure 5. pH profile of HPTS-Cys-MA at two different excitations, Em = 532 nm.
Shows pH profile of HPTS-CysMA at two different excitation wavelengths.
Figure 6. Glucose Response of HPTS-CysMA/3,3'-oBBV in hydrogel. Shows the glucose response of HPTS-CysMA/3,3'-oBBV in a hydrogel.
Figure 7 Fluorescence Spectra of HPTS-CysMA and HPTS-LysMA. Shows a comparison of the fluorescence spectra of HPTS-Cys-MA and HPTS-Lys-MA. (1 x 10-5 M);
Ex Slit 8 nm, Em Slit 12 nm.
Figure 8 Comparison of Stem-Volmer Quenching Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV, [Dye] = 1x10-5 M. Shows a comparison of 3,3'-oBBV Stern-Volmer quenching study using HPTS-Cys-MA and HPTS-Lys-MA.
Figure 9 Comparison of Glucose Modulation Using HPTS-LysMA and HPTS-CysMA with 3,3'-oBBV; [Dye] = Ix10-5 M; Q/D = 150. Shows a comparison glucose modulation using HPTS-Cys-MA and HPTS-Lys-MA with 3,3'-oBBV.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Fluorescent Dyes The fluorescent dyes of the invention are derivatives of 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H+ or any other cation. HPTS
exhibits two excitation wavelengths at around 405 nm and around 450 nm, which correspond to the absorption wavelengths of the acid and its conjugate base, respectively. The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. The dyes maybe used with a quencher comprising boronic acid, such as 3,3'-oBBV.
A generic structure of dyes in accordance with preferred embodiments of the present invention is:
H O
N-S OH
R
H 0~ 0 H
N-S S-N
ii n 1 2 wherein:
i -C_R
RZ is H
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03, O-COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
4 u R is -C-R5;
Fluorescent Dyes The fluorescent dyes of the invention are derivatives of 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H+ or any other cation. HPTS
exhibits two excitation wavelengths at around 405 nm and around 450 nm, which correspond to the absorption wavelengths of the acid and its conjugate base, respectively. The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. The dyes maybe used with a quencher comprising boronic acid, such as 3,3'-oBBV.
A generic structure of dyes in accordance with preferred embodiments of the present invention is:
H O
N-S OH
R
H 0~ 0 H
N-S S-N
ii n 1 2 wherein:
i -C_R
RZ is H
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03-, HP03, O-COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
4 u R is -C-R5;
Y-(CH R6 Yd(CHZ)-0HCH2~R6 R5 is selected from the group consisting of 2)n and " n n wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and 0;
R6 is selected from the group consisting of NHR~, OR~ and CO2H; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
Another generic structure of dyes in accordance with preferred embodiments of the present invention is:
R$ NN-S OH
H
R$ N--l-N_S SNN R$
O O O
H H
O
where:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, CO2- and ), and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R4 n is -C-R5;
-(CHz)-R9 HCH201H0H2H9 R8 is selected from the group consisting of n and n n wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR'O and CO?H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
R6 is selected from the group consisting of NHR~, OR~ and CO2H; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
Another generic structure of dyes in accordance with preferred embodiments of the present invention is:
R$ NN-S OH
H
R$ N--l-N_S SNN R$
O O O
H H
O
where:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, CO2- and ), and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R4 n is -C-R5;
-(CHz)-R9 HCH201H0H2H9 R8 is selected from the group consisting of n and n n wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR'O and CO?H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
The structure of HPTS-Cys-MA is as follows:
Bu4NO43S
N H p H
H S n O
O O Bu4NO3S 1-1 I I SO3NBu4 II H H p O H H
N I i N,N
II N S S N
O O H O O H O O
HPTS-CysMA
As indicated in the generic structures above, substitutions other than Cys-MA
on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. For exmple, either L or D
stereoisomers of cysteic acid may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to HPTS-CysMA shown above, other counterions besides NBu4+ may be used, including positively charged metals, e.g., Na+. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc. functional groups.
For comparison, the structure of HPTS-LysMA is pictured below as follows:
-~-NH
NaO2C ~
( \ ~
NaO2C ~ , CO2Na O
~HN
H~-HPTS-LysMA 0 First Method of making the generic class of compounds to which HPTS-Cys-MA
belongs A first method of making the generic class of compounds to which HPTS-Cys-MA
belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:
Bu4NO43S
N H p H
H S n O
O O Bu4NO3S 1-1 I I SO3NBu4 II H H p O H H
N I i N,N
II N S S N
O O H O O H O O
HPTS-CysMA
As indicated in the generic structures above, substitutions other than Cys-MA
on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. For exmple, either L or D
stereoisomers of cysteic acid may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to HPTS-CysMA shown above, other counterions besides NBu4+ may be used, including positively charged metals, e.g., Na+. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc. functional groups.
For comparison, the structure of HPTS-LysMA is pictured below as follows:
-~-NH
NaO2C ~
( \ ~
NaO2C ~ , CO2Na O
~HN
H~-HPTS-LysMA 0 First Method of making the generic class of compounds to which HPTS-Cys-MA
belongs A first method of making the generic class of compounds to which HPTS-Cys-MA
belongs is disclosed in accordance with another embodiment of the present invention. The method comprises the following steps:
O O
Z protection coup 0 ling Rs ~
HO R2-NH2 HO R2-NZ s H N R2-NZ
H, 0 Z deprotect N-S OH
HPTS-Cl Rs N ~
H O ~ O H H R NH2 N-S S-N
n ii 2 wherein:
2 -C-Ra R is H
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, O-COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
~~
R4 is -C-R5;
5 Y-(CH2)-R6 Y~(CH2nOHCH2~R6 Rls selected from the group consisting of n and n n wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and 0;
R6 is selected from the group consisting of NHR7, OR7 and CO-)H;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).
Z protection coup 0 ling Rs ~
HO R2-NH2 HO R2-NZ s H N R2-NZ
H, 0 Z deprotect N-S OH
HPTS-Cl Rs N ~
H O ~ O H H R NH2 N-S S-N
n ii 2 wherein:
2 -C-Ra R is H
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, O-COZ- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
~~
R4 is -C-R5;
5 Y-(CH2)-R6 Y~(CH2nOHCH2~R6 Rls selected from the group consisting of n and n n wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and 0;
R6 is selected from the group consisting of NHR7, OR7 and CO-)H;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido; and Z is an amino protecting group selected from the group consisting of phthalimido, Boc and Fmoc).
Second method of making the generic class of compounds to which HPTS-Cys-MA
belongs A second method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention.
The method comprises the steps of:
N-~ OH
0 O H O ( HPTS-CI
HO R3 NEt3, CH2CI2 R3 R3 HO\~ ~ \ I Q ~yOH
N -S '` S-H
H
R$-NH2 EDC,HOBt NEt3, CH2CI2 R$ N N-~ OH
H
\
Rs~H_S S H~ Rs wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
-(CH2)-R9 HCH2OHCH2R9 R8 is selected from the group consisting of n and " n "
wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR" and CO2H; and Rl0 is H or an ethylenically unsaturated group selected from the gi-oup consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
First Specific Method of Synthesizing HPTS-Cys-MA
Cysteic acid 1 (0.5 mmols, 94 mg-L stereoisomer was used in this synthesis;
however, D stereoisomer may also be used) was treated with an aqueous solution of tetrabutylammonium hydroxide (0.5 mmols, 4 mL of 0.125 M solution) at room temperature (scheme 1). After stirring for 30 min, the solution was lyophilized to give 2 and the residue was dissolved in dichloromethane (2 mL). Triethylamine (0.6 mmols, 61 ing) was added followed by the dropwise addition of HPTS-Cl (0.1 mmols, 52 mg) in dichloromethane (2 mL). The mixture stirred for 18 h at room temperature and was then concentrated in vacuo. The residue was dissolved in hot isopropyl alcohol and loaded onto a Biotage SPI 25M silica gel cartridge and eluted with NH40H:isopropyl alcohol (1:3) to give HPTS-CysOH as a yellow powder (0.024 mrnols, 39 mg, 24%). 'H NMR (D,O, MHz) S 0.85 (t, J= 7.4 Hz, 36H), 1.20 (s, J= 7.4 Hz, 24H) 1.44 (m, 24H), 2.94 (m, 24H), 3.24 (m, 6H), 4.31 (m, 3H), 8.19 (d, J= 16.8 Hz, 2H), 8.36 (d, J= 9.0 Hz, 1 H), 8.50 (d, J=
9.3 Hz, 1 H), 8.64 (d, J= 9.3 Hz, I H), 8.71 (d, J= 7.1 Hz, 1 H), 8.90 (m, 4H), 9.19 (d, J=
12.0 Hz, 2H).
Scheme I
O
CI-s OAc o ~
W-I
O O Bu4NO3S
CI-S S-CI HO O
OH
0 NBu4OH 0 HPTS-CI
NHZ NHZ
HO H20 HO NEt3, CH2CI2 Bu4NO3 N~ I I S03NBu4 S03H S03NBu4 HO~ oS S~ N
2 -~OH
O H O O H O
HPTS-CysOH
To a solution of HPTS-CysOH (0.0183 minols, 30 mg) in DMF (1 mL) was added N-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (0.055 mmols 10.5 mg), 1-hydroxybenzotriazole (HOBT) (0.055 mmols, 7.4 mg), N,N,N;N'-tetramethyl-O-(1H-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU) (0.055 mmols, 21 mg), and N,N'-diisopropylethylamine (DIEA) (0.183 mmols, 24 mg). After the solution was stirred at room temperature for 20 min, N-(3-aminopropyl)methacrylamide hydrochloride was added and the mixture was stirred for 48 h. The reaction mixture was precipitated with acetone:ether (5:1, 10 mL) to give an oily residue. The residue was triturated with acetone (10 mL) and sonicated for 30 min to give HPTS-CysMA as a crude mixture (35 mg of orange powder).
Scheme 2 0 Bu4NO3S
II H H
N'~~ NH3G N ~
H NS OH
O O H O
EDC, HBtu, HOBt HPTS-CysOH
DIEA, DMF Bu4NO3S ~ I I SO3NBu4 -N N"/_'N~
NN N-O OS
O O H O O H O O
HPTS-CysMA
Second Specific Method of Synthesizing HPTS-Cys-MA
Step 1: Synthesis of TBCys.
O a NHz NBu40H, H20 HO HOK,~NH2 SO3H S03N Bu4 cysteic acid TBCys In a 500-mL beaker equipped with a magnetic stirring bar, (L)-Cysteic acid (129.24 mmols, 24.1913 g) was dissolved in H2O (100 mL) and treated with tetrabutylammonium hydroxide (129.24 mmols, 129.24 mL, 128.59 g of a 1.0 M aqueous solution). The mixture was stirred at room temp for 30 min and then frozen using a low temperature (dry ice/2-propanol) bath. The solid was lyophilized over three days to give a glassy material that was re-dissolved in CH2C12 (300 mL). The solution was evaporated to dryness in a 500-mL
flask to give TBCys as a white foam. Yield: 53.3756 g, 129 mmols, 100 %.
Step 2: Synthesis of Phth acid:
o a o NHz + O I NPhth DIEA
HO / CHC13, DIEA HO +
S03NBu4 0 reflux, 20 h SO NBu ~~~ % 3 4 TBCys Phth acid In a 500-mL flask equipped with a magnetic stirring bar, TBCys (129 mmols, 53.1936 g) was dissolved in CHC13 (129 mL), and N,N'-diisopropylethyl amine (65 mmols, 8.385 g, 11.3 mL) was added followed by phthalic anhydride (129 mmols, 19.10748 g) and 4-angstrom molecular sieves (50 mL); the inixture was refluxed for 48 h. The mixture was filtered through a 600-mL glass fritted funnel and the filtrate was concentrated in vacuo and washed with diethyl ether (2 x 100 mL) and dried under reduced pressure to give Phth acid complexed with N,N'-diisopropylethyl amine. Yield: 70 g, 129 mmols, 100 %. 'H
NMR
(CDC13, 500 MHz) S 0.95 (t, J= 7.4 Hz, 12H), 1.30 (m, 8H), 1.38 (q, J= 7.4 Hz, 8H), 1.61 (m, 8 H), 2.96 (q, J= 7.4 Hz, 1 H), 3.23 (m, 8H), 3.55 (sept, J= 6.7, 1 H), 3.62 (m, 1 H), 3.86 (dd, Jt = 5 Hz, J2 = 9.4 Hz, 1 H), 5.31 (dd, J, = 5.4 Hz, J2 = 1.2 Hz, l H), 7.65 (q, J= 3 Hz, 2H), 7.55 (q, J= 3 Hz, 2H); 13C NMR (CDC13, 125 MHz) 6 12.0, 13.8, 18.1, 19.8, 24.0, 41.7, 50.4, 51.0, 53.1, 58.7, 123.0, 132.8, 133.52, 167.9, 170.7; HPLC
supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, k = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, Rt = 5.9 min.
Step 3: Synthesis of Phth MA:
NPhth HO + "Jf%H~~NH3CI EDC, HOBT, NEt, H~\H~NPhth S03NBu4 CHzCIZ
Phth MA S03NBu4 Phth acid 72%
In a 250-mL round bottom flask equipped with a magnetic stirring bar, Phth acid (24.9 mmols, 13.46 g) was dissolved in CH2C12 (85 mL) at 0 C and EDC (27 mmols, 5.157 g), HOBT (27 mmols, 3.645 g), and triethylamine (54 mmols, 5.4 g, 7.5 mL) were added sequentially; the mixture was stirred under nitrogen for 20 inin. N-(3-Aminopropyl)methacrylamide hydrochloride (27 mmols, 4.806 g) was added and the mixture was allowed to reach room temperature over 2 h and then was stirred for an additional 14 h at room temp. The solution was treated with sat. NaHCO3 (100 mL) and extracted with CHZCI2 (3 x 20 mL). The CH2CI2 layer was dried over MgS04 and concentrated in vacuo to give an orange oil that was loaded onto a Biotage KP-sil 40M
cartridge. The material was purified via gradient elution with 5 to 15 %
MeOH/CHZCIZ.
The product was isolated as a white foam, yield 72 %. 'H NMR (CDC13, 500 MHz) 0.99 (t, J= 7.4 Hz, 12H), 1.44 (sext, J= 7.4 Hz, 8H), 1.66 (m, I OH), 1.89 (s, 3H), 3.28 (m, I 1 H), 3.38 (sext, 2H), 3.96 (dd, Jt = 9 Hz, J~ = 5.9 Hz, I H), 5.22 (t, J=
1.4 Hz, 1 H), 5.44 (dd, Ji = 1.9 Hz, J2 = 9.0 Hz, 1 H), 5.69 (s, 1 H), 5.91 (t, J = 6.0 Hz, 1 H), 7.70 (m, 2H), 7.82 (m, 2H), 9.09 (t, J= 5.8 Hz, IH); 13C NMR (CDC13, 125 MHz) 6 13.8, 18.7, 19.8, 24.1, 29.1, 36.0, 36.4, 50.5, 53.2, 58.9, 119.6, 123.4, 132.3, 134.0, 140.0, 167.9, 168.5, 169.3;
belongs A second method of making the generic class of compounds to which HPTS-Cys-MA belongs is disclosed in accordance with another embodiment of the present invention.
The method comprises the steps of:
N-~ OH
0 O H O ( HPTS-CI
HO R3 NEt3, CH2CI2 R3 R3 HO\~ ~ \ I Q ~yOH
N -S '` S-H
H
R$-NH2 EDC,HOBt NEt3, CH2CI2 R$ N N-~ OH
H
\
Rs~H_S S H~ Rs wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of S03, HP03-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
-(CH2)-R9 HCH2OHCH2R9 R8 is selected from the group consisting of n and " n "
wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR" and CO2H; and Rl0 is H or an ethylenically unsaturated group selected from the gi-oup consisting of methacryloyl, acryloyl, styryl, acrylamide and methacrylamido.
First Specific Method of Synthesizing HPTS-Cys-MA
Cysteic acid 1 (0.5 mmols, 94 mg-L stereoisomer was used in this synthesis;
however, D stereoisomer may also be used) was treated with an aqueous solution of tetrabutylammonium hydroxide (0.5 mmols, 4 mL of 0.125 M solution) at room temperature (scheme 1). After stirring for 30 min, the solution was lyophilized to give 2 and the residue was dissolved in dichloromethane (2 mL). Triethylamine (0.6 mmols, 61 ing) was added followed by the dropwise addition of HPTS-Cl (0.1 mmols, 52 mg) in dichloromethane (2 mL). The mixture stirred for 18 h at room temperature and was then concentrated in vacuo. The residue was dissolved in hot isopropyl alcohol and loaded onto a Biotage SPI 25M silica gel cartridge and eluted with NH40H:isopropyl alcohol (1:3) to give HPTS-CysOH as a yellow powder (0.024 mrnols, 39 mg, 24%). 'H NMR (D,O, MHz) S 0.85 (t, J= 7.4 Hz, 36H), 1.20 (s, J= 7.4 Hz, 24H) 1.44 (m, 24H), 2.94 (m, 24H), 3.24 (m, 6H), 4.31 (m, 3H), 8.19 (d, J= 16.8 Hz, 2H), 8.36 (d, J= 9.0 Hz, 1 H), 8.50 (d, J=
9.3 Hz, 1 H), 8.64 (d, J= 9.3 Hz, I H), 8.71 (d, J= 7.1 Hz, 1 H), 8.90 (m, 4H), 9.19 (d, J=
12.0 Hz, 2H).
Scheme I
O
CI-s OAc o ~
W-I
O O Bu4NO3S
CI-S S-CI HO O
OH
0 NBu4OH 0 HPTS-CI
NHZ NHZ
HO H20 HO NEt3, CH2CI2 Bu4NO3 N~ I I S03NBu4 S03H S03NBu4 HO~ oS S~ N
2 -~OH
O H O O H O
HPTS-CysOH
To a solution of HPTS-CysOH (0.0183 minols, 30 mg) in DMF (1 mL) was added N-ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (0.055 mmols 10.5 mg), 1-hydroxybenzotriazole (HOBT) (0.055 mmols, 7.4 mg), N,N,N;N'-tetramethyl-O-(1H-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU) (0.055 mmols, 21 mg), and N,N'-diisopropylethylamine (DIEA) (0.183 mmols, 24 mg). After the solution was stirred at room temperature for 20 min, N-(3-aminopropyl)methacrylamide hydrochloride was added and the mixture was stirred for 48 h. The reaction mixture was precipitated with acetone:ether (5:1, 10 mL) to give an oily residue. The residue was triturated with acetone (10 mL) and sonicated for 30 min to give HPTS-CysMA as a crude mixture (35 mg of orange powder).
Scheme 2 0 Bu4NO3S
II H H
N'~~ NH3G N ~
H NS OH
O O H O
EDC, HBtu, HOBt HPTS-CysOH
DIEA, DMF Bu4NO3S ~ I I SO3NBu4 -N N"/_'N~
NN N-O OS
O O H O O H O O
HPTS-CysMA
Second Specific Method of Synthesizing HPTS-Cys-MA
Step 1: Synthesis of TBCys.
O a NHz NBu40H, H20 HO HOK,~NH2 SO3H S03N Bu4 cysteic acid TBCys In a 500-mL beaker equipped with a magnetic stirring bar, (L)-Cysteic acid (129.24 mmols, 24.1913 g) was dissolved in H2O (100 mL) and treated with tetrabutylammonium hydroxide (129.24 mmols, 129.24 mL, 128.59 g of a 1.0 M aqueous solution). The mixture was stirred at room temp for 30 min and then frozen using a low temperature (dry ice/2-propanol) bath. The solid was lyophilized over three days to give a glassy material that was re-dissolved in CH2C12 (300 mL). The solution was evaporated to dryness in a 500-mL
flask to give TBCys as a white foam. Yield: 53.3756 g, 129 mmols, 100 %.
Step 2: Synthesis of Phth acid:
o a o NHz + O I NPhth DIEA
HO / CHC13, DIEA HO +
S03NBu4 0 reflux, 20 h SO NBu ~~~ % 3 4 TBCys Phth acid In a 500-mL flask equipped with a magnetic stirring bar, TBCys (129 mmols, 53.1936 g) was dissolved in CHC13 (129 mL), and N,N'-diisopropylethyl amine (65 mmols, 8.385 g, 11.3 mL) was added followed by phthalic anhydride (129 mmols, 19.10748 g) and 4-angstrom molecular sieves (50 mL); the inixture was refluxed for 48 h. The mixture was filtered through a 600-mL glass fritted funnel and the filtrate was concentrated in vacuo and washed with diethyl ether (2 x 100 mL) and dried under reduced pressure to give Phth acid complexed with N,N'-diisopropylethyl amine. Yield: 70 g, 129 mmols, 100 %. 'H
NMR
(CDC13, 500 MHz) S 0.95 (t, J= 7.4 Hz, 12H), 1.30 (m, 8H), 1.38 (q, J= 7.4 Hz, 8H), 1.61 (m, 8 H), 2.96 (q, J= 7.4 Hz, 1 H), 3.23 (m, 8H), 3.55 (sept, J= 6.7, 1 H), 3.62 (m, 1 H), 3.86 (dd, Jt = 5 Hz, J2 = 9.4 Hz, 1 H), 5.31 (dd, J, = 5.4 Hz, J2 = 1.2 Hz, l H), 7.65 (q, J= 3 Hz, 2H), 7.55 (q, J= 3 Hz, 2H); 13C NMR (CDC13, 125 MHz) 6 12.0, 13.8, 18.1, 19.8, 24.0, 41.7, 50.4, 51.0, 53.1, 58.7, 123.0, 132.8, 133.52, 167.9, 170.7; HPLC
supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, k = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, Rt = 5.9 min.
Step 3: Synthesis of Phth MA:
NPhth HO + "Jf%H~~NH3CI EDC, HOBT, NEt, H~\H~NPhth S03NBu4 CHzCIZ
Phth MA S03NBu4 Phth acid 72%
In a 250-mL round bottom flask equipped with a magnetic stirring bar, Phth acid (24.9 mmols, 13.46 g) was dissolved in CH2C12 (85 mL) at 0 C and EDC (27 mmols, 5.157 g), HOBT (27 mmols, 3.645 g), and triethylamine (54 mmols, 5.4 g, 7.5 mL) were added sequentially; the mixture was stirred under nitrogen for 20 inin. N-(3-Aminopropyl)methacrylamide hydrochloride (27 mmols, 4.806 g) was added and the mixture was allowed to reach room temperature over 2 h and then was stirred for an additional 14 h at room temp. The solution was treated with sat. NaHCO3 (100 mL) and extracted with CHZCI2 (3 x 20 mL). The CH2CI2 layer was dried over MgS04 and concentrated in vacuo to give an orange oil that was loaded onto a Biotage KP-sil 40M
cartridge. The material was purified via gradient elution with 5 to 15 %
MeOH/CHZCIZ.
The product was isolated as a white foam, yield 72 %. 'H NMR (CDC13, 500 MHz) 0.99 (t, J= 7.4 Hz, 12H), 1.44 (sext, J= 7.4 Hz, 8H), 1.66 (m, I OH), 1.89 (s, 3H), 3.28 (m, I 1 H), 3.38 (sext, 2H), 3.96 (dd, Jt = 9 Hz, J~ = 5.9 Hz, I H), 5.22 (t, J=
1.4 Hz, 1 H), 5.44 (dd, Ji = 1.9 Hz, J2 = 9.0 Hz, 1 H), 5.69 (s, 1 H), 5.91 (t, J = 6.0 Hz, 1 H), 7.70 (m, 2H), 7.82 (m, 2H), 9.09 (t, J= 5.8 Hz, IH); 13C NMR (CDC13, 125 MHz) 6 13.8, 18.7, 19.8, 24.1, 29.1, 36.0, 36.4, 50.5, 53.2, 58.9, 119.6, 123.4, 132.3, 134.0, 140.0, 167.9, 168.5, 169.3;
HPLC supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, Rt = 6.6 min.
Step 4: Synthesis of AminoCysMA:
N~NPhth HzN_NHZ HZO ~NHz ~~ N N
H H EtOH H H
SO3NBu4 80 C, 2 h S03NBu4 PhthMA AminoCysMA
In a 100-anL round bottom flask equipped with a magnetic stirring bar, PhthMA
(2.59 mmols, 1.7225 g) was dissolved in ethanol (20 mL) and hydrazine monohydrate (2.59 mmols, 0.130 g, 0.126 mL) was added and the mixture was heated at 80 C for two hours.
The solution was cooled to room temperature and CH2CI2 (20 mL) was added. The precipitate that was fonned was filtered using a fritted funnel and washed with additional CH2Cl2 (10 mL) and the filtrate was concentrated in vacuo. The residue was dissolved in CH2CI2 (5 mL) and loaded onto a Biotage KP-NH 40M cartridge and eluted with 1%
to 15 % MeOH/CH~CI,?. The fractions were collected and concentrated in vacuo to give aminoCysMA as a colorless oil. Yield: 60 %.'H NMR (CD3OD, 500 MHz) b 1.03 (t, J=
7.4 Hz, 12H), 1.42 (sext, J= 7.4 Hz, 8H), 1.66 (m, 8H), 1.95 (s, 3H), 2.87 (q, J, = 9.4 Hz, J2 = 4.4 Hz, 1H), 3.23 (m, IOH), 3.81 (dd, J, = 3.3 Hz, J2 = 6.0 Hz, 1H), 5.37 (s, 1H), 5.73 (s, 1H); HPLC supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, k = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, Rt = 3.5 min.
Step 5: S_ynthesis of HPTS-Cys-MA:
Nao3S
~N~~N\~ p II N ~ OH
0 0 1. HPTS-CI 0 0 H 0 H H ~NH2 2. NaOH
3. ion exchange Na03S ~ I I S03Na S03NBu4 4. PS resin N_,NNS R~ I Q S ~NN~
N
AminoCysMA 0 0 H O 11 0 H O 0 HPTS-TriCys-MA
In a 50-mL round bottom flask, AminoCysMA (1.09 mmols, 0.5827 g) was dissolved in CHZC12 (10 inL) and HPTS-Cl (0.29 mmols, 0.163 g) was added.
Triethylamine (1.1 mmols, 0.153 mL) was added and the mixture was stirred at room temperature for 16 h. The red solution was treated with I M NaOH (10 mL), stirred for 30 min., and the two layers were separated in a separatory funnel. The orange-aqueous layer was passed through a column of Dowex 50W resin (in the H+ form) to give a yellow/green solution with a pH = 4 as determined by pH paper. The aqueous solution was then passed through a column of Dowex 50W (in the Na+ form) to obtain the crude sodium salt of HPTS-CysMA. The solution was adsorbed onto polystyrene-divinylbenzene resin (250 g) and washed with H20 (5 x 500 mL). The washings were kept and the adsorbed material was removed from the resin with MeOH (1 L). The MeOH/water extract was evaporated to dryness after multiple co-evaporations with fresh MeOH (4 x 500 mL) and the residue was re-dissolved in MeOH (0.5 mL). Acetone (15 mL) was added and the precipitate was collected by centrifugation and dried under a stream of argon to give HPTS-Cys-MA as an orange/yellow solid. Additional product was isolated from the washings using the same MeOH-extraction procedure. Yield: 40 %. 'H-NMR (500 MHz, D20, ppm): 1.18-1.09 (m, 6H), 1.76-1.53 (m, 9H), 2.73-2.23 (m, 12H); HPLC supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, FLD detector, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, R, =
11.6 min; MALDI-TOF for C46H58N9Na3O22S6 [MH]+: 1350, [MH-Na+H]+:1328, [MH-2Na+2H]+: 1306, [MH-3Na+3H]+: 1284 (major).
Quenchers As used herein, the term "quencher" refers to a compound that reduces the emission of a fluorescent dye, e.g., HPTS-Cys-MA, when in its presence.
In some embodiinents, a quencher moiety provides glucose recognition. Such moieties preferably comprise an aromatic boronic acid. More specifically, the boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen) in which the boronic acid reacts reversibly or irreversibly with glucose in aqueous, organic or combination media to form boronate esters. The extent of the reaction is related to glucose concentration in the medium.
Bis-onium salts are prepared from conjugated heterocyclic aromatic dinitrogen compounds. The conjugated heterocyclic aromatic dinitrogen are, e.g., dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes, phenanthrolines, and diazafluorenes. It is understood that all isomers of said conjugated heterocyclic aromatic dinitrogen compounds in which both nitrogens can be substituted are useful in this invention. Boronic acid-substituted viologens and boronic acid-substituted polyviologens are described in detail in co-pending U.S.
Application No. 11/671,880; incorporated herein in its entirety by reference thereto.
In other embodiments, pyridinium boronic acid quenchers are used in combination with the dyes of the present invention. Pyridinium boronic acid quenchers are described in detail in U.S. Provisional Application No. 60/915,372; incoiporated herein in its entirety by reference thereto.
In one preferred embodiment, 3,3'-oBBV may be used as a quenclier moiety. The structure of 3,3'-oBBV is:
O,, NH
2Br NH
N- N
(HO)zB 6 ~ B(OH)2 3,3'-oBBV
Functional Analysis of Dyes HPTS-Cys-MA was tested in solution using the fluorimeter to determine how it compares with HPTS-LysMA. Stem-Volmer and glucose response studies were carried out back to back under identical conditions to ensure direct comparison.
Solution Studies To a solution of HPTS-CysMA (1 X 10-5 M in pH 7.4 PBS) was added increasing amounts of 3,3'-oBBV (30 mM in MeOH) and the fluorescence emission measured after each addition. Figure 1 gives the relative emission change (Stern-Volmer curve) upon addition of 3,3'-oBBV indicating the quenching of HPTS-CysMA with 3,3-oBBV.
The fluorimeter settings were as follows: 1% attenuation, ex slit 8 nm, em slit 12 nm, 486 nm ex X, 537 nm em X.
HPTS-CysMA (1 x 10-5 M) and 3,3'-oBBV (3 x 10-3 M) were titrated with a stock solution of glucose (31250 mg/dL) in pH 7.4 PBS and the fluorescence emission measured after each addition of glucose The relative change upon addition of glucose is given in Figure 2.
Polymer Studies HPTS-CysMA (1 mg), N,1V-dimethylacrylamide (400 mg), N,N"-methylenebisacrylamide (8 mg), HCI (10 L of I M solution), and VA-044 (1 mg) were dissolved in water and diluted to I mL in a volumetric flask. The solution was freeze-pump-thawed (3x), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55 C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and its fluorescence excitation and emission spectra obtained (Figure 3).
The film was tested in a flow cell configuration at various pHs (initially at pH 5.1;
changed to pH 5.75, 6.26, 6.5, 6.9, 7.4, 8.02, and then back to pH 7.4) at two different excitation wavelengths (418 nm and 486 nm) and was monitored at one emission wavelength (532 nm) over time (Figure 4). The fluorimeter settings were as follows: ex slit 5 nm, em slit 3.5 nm, 515 nm cutoff filter, 418 nm ex k, 486 nm ex k, 532 nm em k.
The pH profile is summarized in Figure 5.
HPTS-CysMA (2 mg), 3,3'-oBBV (15 mg), N,N'-dimethylacrylamide (400 mg), N,N'-methylenebisacrylamide (8 mg), HCI (10 L of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to I mL in a volumetric flask. The solution was freeze-pump-thawed (3X), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55 C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and was tested in a flow cell configuration with increasing amounts of glucose (0, 50, 100, 200, 400 mg/dL). The relative fluorescence change upon addition of glucose is given in Figure 6. The fluorimeter settings were as follows: ex slit 8 nm, em slit 3.5 nm, 515 nm cutoff filter, 486 nm ex a,, 532 nm em a,.
Comparison Studies A comparison of the fluorescence spectra of the CysMA and LysMA dyes in solution is shown in Figure 7. The CysMA dye is blue-shifted relative to the LysMA dye.
A comparison of the Stern-Volmer quenching study for CysMA and LysMA in solution is given in Figure 8 and the glucose response is given in Figure 9.
HPTS-CysMA is quenched more effectively with 3,3'-oBBV than is HPTS-LysMA.
HPTS-CysMA forms a stronger complex because of the sulfonic acids than does HPTS-LysMA, which has carboxylic acids; the tighter complex leads to a greater glucose response. For this reason, dyes substituted with sulfonate groups are preferred.
Glucose Sensors In one preferred embodiment, a device is disclosed for determining blood glucose concentration. The device comprises a sensor comprising an optical fiber sized for deployment intravascularly. The sensor further comprises a water-insoluble polymer matrix, wherein the polymer matrix is permeable to glucose; a fluorescent dye, as disclosed herein, associated with the polymer matrix; a quencher as disclosed herein, adapted to reversibly bind an amount of glucose related to the blood glucose concentration, wherein the quencher is also associated with the polymer matrix and operably coupled to the fluorescent dye, and wherein the quencher is configured to modulate the light emitted by the fluorescent dye related to the amount of bound glucose; at least one excitation light source; and an emission light detector.
A method is also disclosed for determining blood glucose concentration. The method comprises the steps of: providing the device described above; inserting the sensor into a blood vessel; irradiating the sensor at an excitation wavelength;
detecting a fluorescence emission of the sensor at an emission wavelength; and determining the blood glucose concentration.
In some embodiments, for use in vitro not involving a moving stream, the sensing components are used as individual (discrete) components. The dye and quencher are mixed together in liquid solution, analyte is added, the change in fluorescence intensity is measured, and the components are discarded. Polymeric matrices that can be used to trap the sensing components to prevent leaching need not be present. Optionally, the sensing components are immobilized which allows their use to measure analytes in a moving stream.
For in vivo applications, the sensor is used in a moving stream of physiological fluid, preferably blood, which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor assembly.
Thus, for use in vivo, the sensing components are preferably part of an organic polymer sensing assembly.
Soluble dyes and quenchers can be confined by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using soluble sensing moieties that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selectively semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific molecular weight cutoff between the two so that the sensing moieties are quantitatively retained.
Preferably the sensing moieties are immobilized in an insoluble polymer matrix, which is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer, and/or a semipermeable membrane, that is permeable to the analytes of interest.
Step 4: Synthesis of AminoCysMA:
N~NPhth HzN_NHZ HZO ~NHz ~~ N N
H H EtOH H H
SO3NBu4 80 C, 2 h S03NBu4 PhthMA AminoCysMA
In a 100-anL round bottom flask equipped with a magnetic stirring bar, PhthMA
(2.59 mmols, 1.7225 g) was dissolved in ethanol (20 mL) and hydrazine monohydrate (2.59 mmols, 0.130 g, 0.126 mL) was added and the mixture was heated at 80 C for two hours.
The solution was cooled to room temperature and CH2CI2 (20 mL) was added. The precipitate that was fonned was filtered using a fritted funnel and washed with additional CH2Cl2 (10 mL) and the filtrate was concentrated in vacuo. The residue was dissolved in CH2CI2 (5 mL) and loaded onto a Biotage KP-NH 40M cartridge and eluted with 1%
to 15 % MeOH/CH~CI,?. The fractions were collected and concentrated in vacuo to give aminoCysMA as a colorless oil. Yield: 60 %.'H NMR (CD3OD, 500 MHz) b 1.03 (t, J=
7.4 Hz, 12H), 1.42 (sext, J= 7.4 Hz, 8H), 1.66 (m, 8H), 1.95 (s, 3H), 2.87 (q, J, = 9.4 Hz, J2 = 4.4 Hz, 1H), 3.23 (m, IOH), 3.81 (dd, J, = 3.3 Hz, J2 = 6.0 Hz, 1H), 5.37 (s, 1H), 5.73 (s, 1H); HPLC supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, k = 254 nm, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, Rt = 3.5 min.
Step 5: S_ynthesis of HPTS-Cys-MA:
Nao3S
~N~~N\~ p II N ~ OH
0 0 1. HPTS-CI 0 0 H 0 H H ~NH2 2. NaOH
3. ion exchange Na03S ~ I I S03Na S03NBu4 4. PS resin N_,NNS R~ I Q S ~NN~
N
AminoCysMA 0 0 H O 11 0 H O 0 HPTS-TriCys-MA
In a 50-mL round bottom flask, AminoCysMA (1.09 mmols, 0.5827 g) was dissolved in CHZC12 (10 inL) and HPTS-Cl (0.29 mmols, 0.163 g) was added.
Triethylamine (1.1 mmols, 0.153 mL) was added and the mixture was stirred at room temperature for 16 h. The red solution was treated with I M NaOH (10 mL), stirred for 30 min., and the two layers were separated in a separatory funnel. The orange-aqueous layer was passed through a column of Dowex 50W resin (in the H+ form) to give a yellow/green solution with a pH = 4 as determined by pH paper. The aqueous solution was then passed through a column of Dowex 50W (in the Na+ form) to obtain the crude sodium salt of HPTS-CysMA. The solution was adsorbed onto polystyrene-divinylbenzene resin (250 g) and washed with H20 (5 x 500 mL). The washings were kept and the adsorbed material was removed from the resin with MeOH (1 L). The MeOH/water extract was evaporated to dryness after multiple co-evaporations with fresh MeOH (4 x 500 mL) and the residue was re-dissolved in MeOH (0.5 mL). Acetone (15 mL) was added and the precipitate was collected by centrifugation and dried under a stream of argon to give HPTS-Cys-MA as an orange/yellow solid. Additional product was isolated from the washings using the same MeOH-extraction procedure. Yield: 40 %. 'H-NMR (500 MHz, D20, ppm): 1.18-1.09 (m, 6H), 1.76-1.53 (m, 9H), 2.73-2.23 (m, 12H); HPLC supelcosil LC-8-DB, 5 m, 150 mm x 4.6 mm, FLD detector, gradient elution (30 to 70 % MeOH) with MeOH/TBAP, R, =
11.6 min; MALDI-TOF for C46H58N9Na3O22S6 [MH]+: 1350, [MH-Na+H]+:1328, [MH-2Na+2H]+: 1306, [MH-3Na+3H]+: 1284 (major).
Quenchers As used herein, the term "quencher" refers to a compound that reduces the emission of a fluorescent dye, e.g., HPTS-Cys-MA, when in its presence.
In some embodiinents, a quencher moiety provides glucose recognition. Such moieties preferably comprise an aromatic boronic acid. More specifically, the boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen) in which the boronic acid reacts reversibly or irreversibly with glucose in aqueous, organic or combination media to form boronate esters. The extent of the reaction is related to glucose concentration in the medium.
Bis-onium salts are prepared from conjugated heterocyclic aromatic dinitrogen compounds. The conjugated heterocyclic aromatic dinitrogen are, e.g., dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes, phenanthrolines, and diazafluorenes. It is understood that all isomers of said conjugated heterocyclic aromatic dinitrogen compounds in which both nitrogens can be substituted are useful in this invention. Boronic acid-substituted viologens and boronic acid-substituted polyviologens are described in detail in co-pending U.S.
Application No. 11/671,880; incorporated herein in its entirety by reference thereto.
In other embodiments, pyridinium boronic acid quenchers are used in combination with the dyes of the present invention. Pyridinium boronic acid quenchers are described in detail in U.S. Provisional Application No. 60/915,372; incoiporated herein in its entirety by reference thereto.
In one preferred embodiment, 3,3'-oBBV may be used as a quenclier moiety. The structure of 3,3'-oBBV is:
O,, NH
2Br NH
N- N
(HO)zB 6 ~ B(OH)2 3,3'-oBBV
Functional Analysis of Dyes HPTS-Cys-MA was tested in solution using the fluorimeter to determine how it compares with HPTS-LysMA. Stem-Volmer and glucose response studies were carried out back to back under identical conditions to ensure direct comparison.
Solution Studies To a solution of HPTS-CysMA (1 X 10-5 M in pH 7.4 PBS) was added increasing amounts of 3,3'-oBBV (30 mM in MeOH) and the fluorescence emission measured after each addition. Figure 1 gives the relative emission change (Stern-Volmer curve) upon addition of 3,3'-oBBV indicating the quenching of HPTS-CysMA with 3,3-oBBV.
The fluorimeter settings were as follows: 1% attenuation, ex slit 8 nm, em slit 12 nm, 486 nm ex X, 537 nm em X.
HPTS-CysMA (1 x 10-5 M) and 3,3'-oBBV (3 x 10-3 M) were titrated with a stock solution of glucose (31250 mg/dL) in pH 7.4 PBS and the fluorescence emission measured after each addition of glucose The relative change upon addition of glucose is given in Figure 2.
Polymer Studies HPTS-CysMA (1 mg), N,1V-dimethylacrylamide (400 mg), N,N"-methylenebisacrylamide (8 mg), HCI (10 L of I M solution), and VA-044 (1 mg) were dissolved in water and diluted to I mL in a volumetric flask. The solution was freeze-pump-thawed (3x), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55 C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and its fluorescence excitation and emission spectra obtained (Figure 3).
The film was tested in a flow cell configuration at various pHs (initially at pH 5.1;
changed to pH 5.75, 6.26, 6.5, 6.9, 7.4, 8.02, and then back to pH 7.4) at two different excitation wavelengths (418 nm and 486 nm) and was monitored at one emission wavelength (532 nm) over time (Figure 4). The fluorimeter settings were as follows: ex slit 5 nm, em slit 3.5 nm, 515 nm cutoff filter, 418 nm ex k, 486 nm ex k, 532 nm em k.
The pH profile is summarized in Figure 5.
HPTS-CysMA (2 mg), 3,3'-oBBV (15 mg), N,N'-dimethylacrylamide (400 mg), N,N'-methylenebisacrylamide (8 mg), HCI (10 L of 1 M solution), and VA-044 (1 mg) were dissolved in water and diluted to I mL in a volumetric flask. The solution was freeze-pump-thawed (3X), injected into a mold containing a 0.005" polyimide spacer and polymerized at 55 C for 16 h. The resultant film was placed in pH 7.4 phosphate buffer and was tested in a flow cell configuration with increasing amounts of glucose (0, 50, 100, 200, 400 mg/dL). The relative fluorescence change upon addition of glucose is given in Figure 6. The fluorimeter settings were as follows: ex slit 8 nm, em slit 3.5 nm, 515 nm cutoff filter, 486 nm ex a,, 532 nm em a,.
Comparison Studies A comparison of the fluorescence spectra of the CysMA and LysMA dyes in solution is shown in Figure 7. The CysMA dye is blue-shifted relative to the LysMA dye.
A comparison of the Stern-Volmer quenching study for CysMA and LysMA in solution is given in Figure 8 and the glucose response is given in Figure 9.
HPTS-CysMA is quenched more effectively with 3,3'-oBBV than is HPTS-LysMA.
HPTS-CysMA forms a stronger complex because of the sulfonic acids than does HPTS-LysMA, which has carboxylic acids; the tighter complex leads to a greater glucose response. For this reason, dyes substituted with sulfonate groups are preferred.
Glucose Sensors In one preferred embodiment, a device is disclosed for determining blood glucose concentration. The device comprises a sensor comprising an optical fiber sized for deployment intravascularly. The sensor further comprises a water-insoluble polymer matrix, wherein the polymer matrix is permeable to glucose; a fluorescent dye, as disclosed herein, associated with the polymer matrix; a quencher as disclosed herein, adapted to reversibly bind an amount of glucose related to the blood glucose concentration, wherein the quencher is also associated with the polymer matrix and operably coupled to the fluorescent dye, and wherein the quencher is configured to modulate the light emitted by the fluorescent dye related to the amount of bound glucose; at least one excitation light source; and an emission light detector.
A method is also disclosed for determining blood glucose concentration. The method comprises the steps of: providing the device described above; inserting the sensor into a blood vessel; irradiating the sensor at an excitation wavelength;
detecting a fluorescence emission of the sensor at an emission wavelength; and determining the blood glucose concentration.
In some embodiments, for use in vitro not involving a moving stream, the sensing components are used as individual (discrete) components. The dye and quencher are mixed together in liquid solution, analyte is added, the change in fluorescence intensity is measured, and the components are discarded. Polymeric matrices that can be used to trap the sensing components to prevent leaching need not be present. Optionally, the sensing components are immobilized which allows their use to measure analytes in a moving stream.
For in vivo applications, the sensor is used in a moving stream of physiological fluid, preferably blood, which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor assembly.
Thus, for use in vivo, the sensing components are preferably part of an organic polymer sensing assembly.
Soluble dyes and quenchers can be confined by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using soluble sensing moieties that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selectively semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific molecular weight cutoff between the two so that the sensing moieties are quantitatively retained.
Preferably the sensing moieties are immobilized in an insoluble polymer matrix, which is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer, and/or a semipermeable membrane, that is permeable to the analytes of interest.
The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effect, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. In some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix must not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases.
Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels are established in the art. All useful matrices are defined as being analyte permeable.
?CJC~C
While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All figures, tables, and appendices, as well as patents, applications, and publications, referred to above, are hereby incorporated by reference.
Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels are established in the art. All useful matrices are defined as being analyte permeable.
?CJC~C
While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention. All figures, tables, and appendices, as well as patents, applications, and publications, referred to above, are hereby incorporated by reference.
Claims (13)
1. The compound:
wherein:
R2 is R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R5 is selected from the group consisting of and wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR7, OR7 and CO2H; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
wherein:
R2 is R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R5 is selected from the group consisting of and wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR7, OR7 and CO2H; and R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
2. The compound:
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+
wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R8 is selected from the group consisting of wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR10 and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+
wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R8 is selected from the group consisting of wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR10 and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
3. The compound:
4. The compound of Claim 3, wherein NBu4 is any other counterion.
5. The compound of Claim 3, comprising L, D, or L and D stereoisomers of cysteine.
6. A glucose sensor comprising the compound of Claim 1.
7. The glucose sensor of Claim 6, further comprising a quencher moiety.
8. The glucose sensor of Claim 7, wherein said quencher moiety comprises boronic acid.
9. The glucose sensor of Claim 8, wherein said boronic acid quencher is 3,3'-oBBV.
10. A method of making the compound of Claim 1, comprising the steps of:
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3-, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R5 is selected from the group consisting of and wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR7, OR7 and CO2H;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido; and Z is an amino protecting group selected from the group consisting of Phthalimido, Boc and Fmoc.
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3-, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R5 is selected from the group consisting of and wherein n is equal to 1-10, n' is equal to 2-4 and Y is selected from the group consisting of NH and O;
R6 is selected from the group consisting of NHR7, OR7 and CO2H;
R7 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido; and Z is an amino protecting group selected from the group consisting of Phthalimido, Boc and Fmoc.
11. A method of making the compound of Claim 2, comprising the steps of:
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R8 is selected from the group consisting of wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR10 and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
wherein:
R3 is -(CH2)n -A-M+, wherein n is 1-4, wherein A- is an anionic group selected from the group consisting of SO3, HPO3-, CO2- and and wherein M+ is a cationic group selected from the group consisting of H+, an alkali metal ion, Li+, Na+, K+, Rb+, Cs+, Fr+, an onium ion and NR4+, wherein R is selected from the group consisting of alkyl, alkylaryl and aromatic groups);
R8 is selected from the group consisting of wherein n is equal to 1-10, n' is equal to 2-4;
R9 is selected from the group consisting of NHR10, OR10 and CO2H; and R10 is H or an ethylenically unsaturated group selected from the group consisting of methacryloyl, acryloyl, styryl, acrylamido and methacrylamido.
12. A method of making the compound of Claim 3, comprising the steps of making HPTS-CysOH as follows; and making HPTS-Cys-MA as follows:
13. A method of making the compound of Claim 3, comprising the steps of:
making TBCys as follows:
making Phth acid as follows:
making Phth MA as follows:
making AminoCysMA as follows:
making HPTS-Cys-MA as follows:
making TBCys as follows:
making Phth acid as follows:
making Phth MA as follows:
making AminoCysMA as follows:
making HPTS-Cys-MA as follows:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83308106P | 2006-07-25 | 2006-07-25 | |
| US60/833,081 | 2006-07-25 | ||
| PCT/US2007/074255 WO2008014280A2 (en) | 2006-07-25 | 2007-07-24 | Flourescent dyes for use in glucose sensing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2652025A1 true CA2652025A1 (en) | 2008-01-31 |
Family
ID=38896105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002652025A Abandoned CA2652025A1 (en) | 2006-07-25 | 2007-07-24 | Flourescent dyes for use in glucose sensing |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7417164B2 (en) |
| EP (1) | EP2054476B9 (en) |
| JP (1) | JP5159778B2 (en) |
| AT (1) | ATE514755T1 (en) |
| AU (1) | AU2007276777A1 (en) |
| CA (1) | CA2652025A1 (en) |
| WO (1) | WO2008014280A2 (en) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
| US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
| US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
| US6001067A (en) * | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
| US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US7470420B2 (en) * | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
| US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
| US7828728B2 (en) | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
| JP4708342B2 (en) | 2003-07-25 | 2011-06-22 | デックスコム・インコーポレーテッド | Oxygen augmentation membrane system for use in implantable devices |
| US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8282549B2 (en) | 2003-12-09 | 2012-10-09 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
| US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8060173B2 (en) | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8676287B2 (en) | 2003-08-01 | 2014-03-18 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US8233959B2 (en) | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
| DE602004029092D1 (en) | 2003-12-05 | 2010-10-21 | Dexcom Inc | CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTIC SENSOR |
| US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
| US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
| WO2006127694A2 (en) | 2004-07-13 | 2006-11-30 | Dexcom, Inc. | Analyte sensor |
| US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US20060016700A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7946984B2 (en) | 2004-07-13 | 2011-05-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
| US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
| US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8088097B2 (en) | 2007-11-21 | 2012-01-03 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
| JP2010517693A (en) | 2007-02-06 | 2010-05-27 | グルメトリクス， インコーポレイテッド | Optical system and method for ratiometric measurement of blood glucose concentration |
| US8972196B2 (en) * | 2007-02-06 | 2015-03-03 | Medtronic Minimed, Inc. | Algorithms for calibrating an analyte sensor |
| US7751863B2 (en) | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
| US7824918B2 (en) * | 2007-08-06 | 2010-11-02 | Glumetrics, Inc. | HPTS-Mono and BIS Cys-Ma polymerizable fluorescent dyes for use in analyte sensors |
| CA2684511A1 (en) | 2007-05-01 | 2008-11-13 | Glumetrics, Inc. | Pyridinium boronic acid quenchers for use in analyte sensors |
| WO2008141241A1 (en) * | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
| WO2008141243A2 (en) * | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Device and methods for calibrating analyte sensors |
| WO2008154312A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US9452258B2 (en) | 2007-10-09 | 2016-09-27 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US20090299156A1 (en) * | 2008-02-20 | 2009-12-03 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
| US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| US8682408B2 (en) | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
| WO2009129186A2 (en) * | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
| WO2010005398A1 (en) * | 2008-07-09 | 2010-01-14 | Agency For Science, Technology And Research | Trapping glucose probe in pores of polymer |
| EP2326944B1 (en) | 2008-09-19 | 2020-08-19 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
| US9446194B2 (en) | 2009-03-27 | 2016-09-20 | Dexcom, Inc. | Methods and systems for promoting glucose management |
| JP2013506503A (en) | 2009-09-30 | 2013-02-28 | グルメトリクス， インコーポレイテッド | Sensor with antithrombogenic coating |
| US8467843B2 (en) | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
| WO2011097586A1 (en) | 2010-02-08 | 2011-08-11 | Glumetrics, Inc. | Antioxidant protection of a chemical sensor |
| WO2011113020A1 (en) * | 2010-03-11 | 2011-09-15 | Glumetrics, Inc. | Measurement devices and methods for measuring analyte concentration incorporating temperature and ph correction |
| DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
| JP6046115B2 (en) * | 2011-04-18 | 2016-12-14 | ノビオセンス ビー．ブイ． | Biosensor |
| EP2769226B1 (en) | 2011-07-15 | 2017-05-24 | Medtronic Minimed, Inc. | Combinations of fluorphores and pyridinium boronic acid quenchers for use in analyte sensors |
| CA2850148C (en) | 2011-09-27 | 2020-02-25 | Glumetrics, Inc. | Method for functionalizing a porous membrane covering of an optical sensor to facilitate coupling of an antithrombogenic agent |
| CN105820810B (en) * | 2016-04-27 | 2018-03-30 | 中南大学 | A kind of synthesis and application for identifying cysteine and homocysteine novel fluorescence probe |
| CN115505280A (en) | 2016-12-21 | 2022-12-23 | 普罗菲尤萨股份有限公司 | Polymerizable near infrared dyes |
| JOP20190161A1 (en) | 2016-12-27 | 2017-06-16 | Profusa Inc | Near-ir glucose sensors |
| US20190120785A1 (en) | 2017-10-24 | 2019-04-25 | Dexcom, Inc. | Pre-connected analyte sensors |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5137833A (en) | 1989-09-21 | 1992-08-11 | Russell Anthony P | Method for detecting polyhydroxyl compounds |
| US5512246A (en) | 1989-09-21 | 1996-04-30 | Anthony P. Russell | Method and means for detecting polyhydroxyl compounds |
| GB2284809B (en) | 1993-11-07 | 1998-04-29 | Japan Res Dev Corp | A fluorescent phenylboronic acid suitable for use in the detection of saccharides |
| JP2799837B2 (en) | 1995-03-03 | 1998-09-21 | 科学技術振興事業団 | Boronic acid compounds having a binaphthyl group |
| WO1997019188A1 (en) | 1995-11-22 | 1997-05-29 | Minimed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
| US6002954A (en) | 1995-11-22 | 1999-12-14 | The Regents Of The University Of California | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
| US6766183B2 (en) | 1995-11-22 | 2004-07-20 | Medtronic Minimed, Inc. | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
| WO2002012251A1 (en) | 2000-08-04 | 2002-02-14 | Sensors For Medicine And Science, Inc. | Detection of analytes in aqueous environments |
| US6627177B2 (en) | 2000-12-05 | 2003-09-30 | The Regents Of The University Of California | Polyhydroxyl-substituted organic molecule sensing optical in vivo method utilizing a boronic acid adduct and the device thereof |
| US6653141B2 (en) | 2000-12-05 | 2003-11-25 | The Regents Of The University Of California | Polyhydroxyl-substituted organic molecule sensing method and device |
| US7470420B2 (en) * | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
| US6800451B2 (en) | 2001-01-05 | 2004-10-05 | Sensors For Medicine And Science, Inc. | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
-
2007
- 2007-07-24 EP EP07799791A patent/EP2054476B9/en active Active
- 2007-07-24 JP JP2009521962A patent/JP5159778B2/en active Active
- 2007-07-24 CA CA002652025A patent/CA2652025A1/en not_active Abandoned
- 2007-07-24 WO PCT/US2007/074255 patent/WO2008014280A2/en active Application Filing
- 2007-07-24 US US11/782,553 patent/US7417164B2/en active Active
- 2007-07-24 AT AT07799791T patent/ATE514755T1/en not_active IP Right Cessation
- 2007-07-24 AU AU2007276777A patent/AU2007276777A1/en not_active Abandoned
-
2008
- 2008-08-22 US US12/197,161 patent/US7767846B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2054476B1 (en) | 2011-06-29 |
| WO2008014280A2 (en) | 2008-01-31 |
| EP2054476A2 (en) | 2009-05-06 |
| WO2008014280A3 (en) | 2008-09-18 |
| ATE514755T1 (en) | 2011-07-15 |
| US7417164B2 (en) | 2008-08-26 |
| AU2007276777A1 (en) | 2008-01-31 |
| JP5159778B2 (en) | 2013-03-13 |
| US20080027245A1 (en) | 2008-01-31 |
| US7767846B2 (en) | 2010-08-03 |
| JP2009544729A (en) | 2009-12-17 |
| EP2054476B9 (en) | 2012-03-14 |
| US20080305506A1 (en) | 2008-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2652025A1 (en) | Flourescent dyes for use in glucose sensing | |
| EP2181160B1 (en) | Hpts-mono cys-ma polymerizable fluorescent dyes for use in analyte sensors | |
| CA2857493C (en) | Combinations of fluorphores and pyridinium boronic acid quenchers for use in analyte sensors | |
| EP2222686B1 (en) | Polyviologen boronic acid quenchers for use in analyte sensors | |
| EP2147003B1 (en) | Pyridinium boronic acid quenchers for use in analyte sensors | |
| AU650425B2 (en) | Method and means for detecting polyhydroxyl compounds | |
| US8202731B2 (en) | HPTS-mono and bis Cys-MA polymerizable fluorescent dyes for use in analyte sensors | |
| WO2002046752A9 (en) | Optical determination of glucose utilizing boronic acid adducts | |
| GB2277096A (en) | Fluorescent ion-selective diaryldiaza crown ether conjugates | |
| WO2007067743A2 (en) | Optical determination of glucose utilizing boronic acid adducts-ii | |
| KR102513508B1 (en) | FLUOROGENIC pH-SENSITIVE DYES, FILM AND KIT COMPRISING THE SAME | |
| CN100549009C (en) | From the solution that contains alpha hydroxy acid or beta-diketon, detect the composition and the method for glucose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |